Cargando…

Aterofisiol(®) in carotid plaque evolution

BACKGROUND: In patients with carotid stenosis, the risk of plaque rupture is related to the composition of the atherosclerotic plaque rather than to its magnitude. In this regard, we evaluated the effects of a supplement, Aterofisiol,(®) containing omega-3 (EPA [eicosapen acid] DHA [docosahexaenoic...

Descripción completa

Detalles Bibliográficos
Autores principales: Amato, Bruno, Compagna, Rita, Amato, Maurizio, Gallelli, Luca, de Franciscis, Stefano, Serra, Raffaele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517514/
https://www.ncbi.nlm.nih.gov/pubmed/26229448
http://dx.doi.org/10.2147/DDDT.S87609
_version_ 1782383200268451840
author Amato, Bruno
Compagna, Rita
Amato, Maurizio
Gallelli, Luca
de Franciscis, Stefano
Serra, Raffaele
author_facet Amato, Bruno
Compagna, Rita
Amato, Maurizio
Gallelli, Luca
de Franciscis, Stefano
Serra, Raffaele
author_sort Amato, Bruno
collection PubMed
description BACKGROUND: In patients with carotid stenosis, the risk of plaque rupture is related to the composition of the atherosclerotic plaque rather than to its magnitude. In this regard, we evaluated the effects of a supplement, Aterofisiol,(®) containing omega-3 (EPA [eicosapen acid] DHA [docosahexaenoic acid]), vitamin K(2), vitamin B(6), vitamin B(12), oligomeric proanthocyanidins (OPC) and resveratrol on the composition of atherosclerotic plaque and on neurological symptoms in patients with carotid stenosis undergoing carotid endarterectomy. METHODS: The study was randomized, prospective, and double-blinded. Eligible patients were of both sexes, with carotid stenosis >70% who underwent endarterectomy. Enrolled patients were randomly allocated to receive either one tablet of acetylsalicylic acid 100 mg (Cardioaspirin(®)) + one tablet of Aterofisiol every 24 hours or one tablet of Cardioaspirin + one tablet of placebo every 24 hours. Each treatment was started 30 days before the surgery and was stopped 5 days before the surgery. The plaques were removed “en bloc” using standard surgical technique. RESULTS: During the study period, 214 patients (135 men and 79 women) were enrolled for intent-to-treat and randomized in two groups: Group A: 107 patients (68 men and 39 women) were treated with Cardioaspirin + Aterofisiol. Group B: 107 patients (67 men and 40 women) were treated with Cardioaspirin + placebo. At the end of the study, 202 patients participated fully (103 patients in Group A and 99 patients in Group B), making up the protocol evaluation population (94.4%). The mean lipid content of removed plaques was significantly lower (P<0.05) in Group A. We recorded a significantly lower incidence of neurological symptoms in Group A in comparison with Group B (P<0.05). CONCLUSION: In the study, Aterofisiol showed to be effective in reducing the amounts of cholesterol and lipids in the plaques and in reducing adverse neurological events in the study group with respect to controls.
format Online
Article
Text
id pubmed-4517514
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-45175142015-07-30 Aterofisiol(®) in carotid plaque evolution Amato, Bruno Compagna, Rita Amato, Maurizio Gallelli, Luca de Franciscis, Stefano Serra, Raffaele Drug Des Devel Ther Original Research BACKGROUND: In patients with carotid stenosis, the risk of plaque rupture is related to the composition of the atherosclerotic plaque rather than to its magnitude. In this regard, we evaluated the effects of a supplement, Aterofisiol,(®) containing omega-3 (EPA [eicosapen acid] DHA [docosahexaenoic acid]), vitamin K(2), vitamin B(6), vitamin B(12), oligomeric proanthocyanidins (OPC) and resveratrol on the composition of atherosclerotic plaque and on neurological symptoms in patients with carotid stenosis undergoing carotid endarterectomy. METHODS: The study was randomized, prospective, and double-blinded. Eligible patients were of both sexes, with carotid stenosis >70% who underwent endarterectomy. Enrolled patients were randomly allocated to receive either one tablet of acetylsalicylic acid 100 mg (Cardioaspirin(®)) + one tablet of Aterofisiol every 24 hours or one tablet of Cardioaspirin + one tablet of placebo every 24 hours. Each treatment was started 30 days before the surgery and was stopped 5 days before the surgery. The plaques were removed “en bloc” using standard surgical technique. RESULTS: During the study period, 214 patients (135 men and 79 women) were enrolled for intent-to-treat and randomized in two groups: Group A: 107 patients (68 men and 39 women) were treated with Cardioaspirin + Aterofisiol. Group B: 107 patients (67 men and 40 women) were treated with Cardioaspirin + placebo. At the end of the study, 202 patients participated fully (103 patients in Group A and 99 patients in Group B), making up the protocol evaluation population (94.4%). The mean lipid content of removed plaques was significantly lower (P<0.05) in Group A. We recorded a significantly lower incidence of neurological symptoms in Group A in comparison with Group B (P<0.05). CONCLUSION: In the study, Aterofisiol showed to be effective in reducing the amounts of cholesterol and lipids in the plaques and in reducing adverse neurological events in the study group with respect to controls. Dove Medical Press 2015-07-23 /pmc/articles/PMC4517514/ /pubmed/26229448 http://dx.doi.org/10.2147/DDDT.S87609 Text en © 2015 Amato et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Amato, Bruno
Compagna, Rita
Amato, Maurizio
Gallelli, Luca
de Franciscis, Stefano
Serra, Raffaele
Aterofisiol(®) in carotid plaque evolution
title Aterofisiol(®) in carotid plaque evolution
title_full Aterofisiol(®) in carotid plaque evolution
title_fullStr Aterofisiol(®) in carotid plaque evolution
title_full_unstemmed Aterofisiol(®) in carotid plaque evolution
title_short Aterofisiol(®) in carotid plaque evolution
title_sort aterofisiol(®) in carotid plaque evolution
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517514/
https://www.ncbi.nlm.nih.gov/pubmed/26229448
http://dx.doi.org/10.2147/DDDT.S87609
work_keys_str_mv AT amatobruno aterofisiolincarotidplaqueevolution
AT compagnarita aterofisiolincarotidplaqueevolution
AT amatomaurizio aterofisiolincarotidplaqueevolution
AT gallelliluca aterofisiolincarotidplaqueevolution
AT defranciscisstefano aterofisiolincarotidplaqueevolution
AT serraraffaele aterofisiolincarotidplaqueevolution